Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
03/2012
03/01/2012US20120053230 TREATMENT OF NEUROLOGICAL DISORDERS BY dsRNA ADMINISTRATION
03/01/2012US20120053220 Novel lipoxygenase inhibitors as neuroprotective agents
03/01/2012US20120053214 The little molecule compound which used for promoting the stem cells hyperplasia and the use thereof
03/01/2012US20120053210 Compounds that modulate intracellular calcium
03/01/2012US20120053207 Antipsychotic treatment based on drd2 or ankk1 snp genotype
03/01/2012US20120053206 Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as KCNQ2/3 modulators
03/01/2012US20120053205 Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators
03/01/2012US20120053204 Substituted quinoline-3-carboxamides as KCNQ2/3 modulators
03/01/2012US20120053203 Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as KCNQ2/3 modulators
03/01/2012US20120053202 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF
03/01/2012US20120053199 Noscapine and analogs and methods related thereto
03/01/2012US20120053191 Oxidated derivatives of triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments
03/01/2012US20120053190 Organic compounds
03/01/2012US20120053189 Btk inhibitors for the treatment of immune mediated conditions
03/01/2012US20120053187 Tri-cyclic pyrazolopyridine kinase inhibitors
03/01/2012US20120053186 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
03/01/2012US20120053182 Methods of alleviating or treating signs and/or symptoms associated with moderate to severe parkinson's disease
03/01/2012US20120053179 Rho-Kinase Inhibitors
03/01/2012US20120053175 Mlk inhibitors and methods of use
03/01/2012US20120053171 Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors
03/01/2012US20120053169 Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
03/01/2012US20120053168 Fused benzoazepines as neuronal nicotinic acetylcholine receptor ligands
03/01/2012US20120053167 Triazine Derivatives as Kinase Inhibitors
03/01/2012US20120053166 4-Oxadiazol-2-YL-Indazoles as Inhibitors of P13 Kinases
03/01/2012US20120053165 Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators
03/01/2012US20120053164 Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd
03/01/2012US20120053159 Isotopologues of lenalidomide
03/01/2012US20120053158 Preparation of an acetyl salicylic acid/glutamic acid complex for oral administration
03/01/2012US20120053147 Thiazolopyrimidinone derivatives as pi3 kinase inhibitors
03/01/2012US20120053145 Aripiprazole complex formulation and method
03/01/2012US20120053138 Formulation of a mixture of free-b-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
03/01/2012US20120053137 Method for Treating Addiction Using Quercetin-Containing Compositions
03/01/2012US20120053134 Pharmaceutical composition for preventing or treating neuronal damage and neurological diseases
03/01/2012US20120053127 Targeted delivery of botulinum toxin to the sphenopalatine ganglion
03/01/2012US20120053126 Injection Paradigm for Administration of Botulinum Toxins
03/01/2012US20120053121 Administration of HB-EGF for the Protection of Enteric Neurons
03/01/2012US20120053120 Treatment of subarachnoid hemorrhage with apo e analogs
03/01/2012US20120052292 Novel medical device coatings
03/01/2012US20120052139 Fragrance composition having good sleep-inducing effect
03/01/2012US20120052132 Compositions and methods for treatment of body weight conditions
03/01/2012US20120052130 Gpr 119 modulators
03/01/2012US20120052121 New combination of active ingredients containing a non steroidal anti inflammatory drug and a colchicoside derivative
03/01/2012US20120052119 Nanoencapsulated delta-9-tetrahydrocannabinol
03/01/2012US20120052113 Transdermal preparation
03/01/2012US20120052098 Liquid ganaxolone formulations and methods for the making and use thereof
03/01/2012US20120052096 Novel dioxo-imidazolidine derivatives, which inhibit the enzyme soat-1, and pharmaceutical and cosmetic compositions containing them
03/01/2012US20120052094 Agonists of Neurotrophin Receptors and Their Use as Medicaments
03/01/2012US20120052088 Pneumococcal vaccine and uses thereof
03/01/2012US20120052086 Vaccine composition for prophylaxis and/or therapy of alzheimer's disease
03/01/2012US20120052077 Therapeutic modulation of vaginal epithelium boundary lubrication
03/01/2012US20120052075 Modulation of the vps10p-domain receptor family for the treatment of mental and behavioural disorders
03/01/2012US20120052070 Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both
03/01/2012US20120052068 Autophilic antibodies and method of making the same
03/01/2012US20120052056 Composition for improving blood circulation containing fermented tea, and pharmaceutical and health-food compositions comprising the same
03/01/2012US20120052053 Compositions and methods for the treatment of altered alpha-synuclein function
03/01/2012US20120052049 Systemic, Allogenic Stem Cell Therapies For Treatment of Diseases in Animals
03/01/2012US20120052019 Certain chemical entities, compositions, and methods
03/01/2012US20120052012 Highly biocompatible dual thermogelling chitosan/glucosamine salt compositions
03/01/2012US20120052005 Combination therapy to improve drug efficiency
03/01/2012CA2809341A1 Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators
03/01/2012CA2809287A1 Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as kcnq2/3 modulators
03/01/2012CA2808680A1 Methods of treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprise the administration of dihydromyricetin
03/01/2012CA2808359A1 Certain chemical entities, compositions, and methods
03/01/2012CA2807968A1 Salt compound
03/01/2012CA2807965A1 Methods for treating antipsychotic-induced weight gain
03/01/2012CA2807062A1 Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
03/01/2012CA2807000A1 Proline sulfonamide derivatives as orexin receptor antagonists
03/01/2012CA2805932A1 Substituted 2-amino-quinoline-3-carboxamides as kcnq2/3 modulators
03/01/2012CA2804824A1 Substituted quinoline-3-carboxamides as kcnq2/3 modulators
02/2012
02/29/2012EP2423685A1 Agent and method for diagnosis on the occurrence of Alzheimer's disease
02/29/2012EP2423311A1 Method for preparing cell pharmaceutical
02/29/2012EP2423207A2 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors
02/29/2012EP2422803A2 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
02/29/2012EP2422802A2 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
02/29/2012EP2422801A2 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
02/29/2012EP2422800A2 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
02/29/2012EP2422799A2 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
02/29/2012EP2422798A2 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
02/29/2012EP2422797A2 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
02/29/2012EP2422796A2 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
02/29/2012EP2422795A2 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
02/29/2012EP2422794A2 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
02/29/2012EP2422787A1 Diazoxide for use in the treatment of amyotrophic lateral sclerosis (als)
02/29/2012EP2422778A1 Titration of tapentadol
02/29/2012EP2421870A2 Modulators of 5-ht receptors and methods of use thereof
02/29/2012EP2421863A1 Substituted naphthyridine derivatives and their medical use
02/29/2012EP2421862A1 Octahydrobenzoisoquinoline modulators of dopamine receptors and uses therefor
02/29/2012EP2421860A1 Azetidinyl diamides as monoacylglycerol lipase inhibitors
02/29/2012EP2421856A1 Azetidinyl diamides as monoacylglycerol lipase inhibitors
02/29/2012EP2421852A1 Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitor
02/29/2012EP2421851A1 Azetidinyl diamides as monoacylglycerol lipase inhibitors
02/29/2012EP2421850A1 3 -azabicyclo [4.1.0]heptanes used as orexin antagonists
02/29/2012EP2421848A1 Azetidinyl diamides as monoacylglycerol lipase inhibitors
02/29/2012EP2421847A1 Azetidinyl diamides as monoacylglycerol lipase inhibitors
02/29/2012EP2421833A1 Resorcinol derivatives as hsp90 inhibitors
02/29/2012EP2421830A2 2,5-disubstituted arylsulfonamide ccr3 antagonists
02/29/2012EP2421829A2 2,5-disubstituted arylsulfonamide ccr3 antagonists
02/29/2012EP2421825A1 Azetidinyl diamides as monoacylglycerol lipase inhibitors
02/29/2012EP2421824A1 Azetidinyl diamides as monoacylglycerol lipase inhibitors
02/29/2012EP2421823A1 Azetidinyl diamides as monoacylglycerol lipase inhibitors
1 ... 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 ... 1833